Anthony leverages more than 35 years of experience, including over a decade spent building & managing a biotechnology company and over 20 years as a management consultant to the pharmaceutical & biotech industries.
Simon has more than two decades of experience managing and advising on strategic and product development issues.
Alastair brings 25 years of strategic planning and product commercialization experience across multiple disease areas in big pharma and start up environments.
Chris leverages 20 years of experience in biopharma drug development, strategy, and business development across multiple modalities and indications. He brings extensive expertise in antivirals, CRISPR gene editing, gene therapies, and gene therapy vectors.
Saadia has experience in technology assessment of a wide range of life science technologies, market opportunity assessment, business-plan development, competitor landscape analysis, due diligence and asset valuations.
Jess is a life science consultant with industry experience working across the drug development pipeline in academic, contract research, biotech, big pharma and regulatory agency roles.
Eugene is an Associate Consultant with a background in neuroimmunology and supports clients on a range of strategy and business development assignments.
Pierre is a senior pharmaceutical executive with over 30 years of experience in the global pharmaceutical industry, with an extensive expertise in oncology. He supports clients across a range of functional disciplines, including clinical, regulatory, manufacturing, quality, strategic market access, commercial and M&A.
Mark Philip has over 30 years’ experience in the Biopharma, Medical Device, Diagnostic and Health IT industries, operating in Europe, the USA and Asia.
Christine is a clinical drug developer with more than 25 years of experience in large pharma companies.
Stuart has significant experience of the life science and medical device industries, with 25 years of global work experience in the USA, Europe, Japan, China and Australasia.
Bill is a clinical drug developer and medical oncologist with more than 20 years’ experience in the biopharma industry.